Dirk Zboralski

3 ta ish

MerLion Pharma (Germany)

1. Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷Lu-FAP-2286: First-in-Humans Results

   Richard P. Baum, Christiane Schuchardt, Aviral Singh +12

   Maqola20213 iqtibos

   ABIABI:AkademIndex/2026.other.340321

2. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization

   Julia Hoellenriegel, Dirk Zboralski, Christian Maasch +5

   MaqolaOAOchiq kirish20132 iqtibos

   ABIABI:AkademIndex/2026.other.071984

3. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy

   Dirk Zboralski, Aileen Hoehne, Anne Bredenbeck +18

   Maqola20222 iqtibos

   ABIABI:AkademIndex/2026.other.340325